

Attorney Docket No.: **PENN-0789**
Inventors: **Siegel et al.**
Serial No.: **10/046,504**
Filing Date: **October 19, 2001**
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1: (currently amended) A surgically implantable drug delivery system for delivery of steady state concentrations of haloperidol to a patient for 5 months or more comprising consisting essentially of a biodegradable polymer or copolymer and haloperidol fabricated into the surgically implantable drug delivery systems an implant via solvent casting and compression molding wherein said drug delivery system which is surgically implanted underneath the skin of a patient and is removable from a patient into which the drug delivery system has been implanted the patient in the event the patient exhibits unwanted side effects following implantation.

Claim 2: (original) The surgically implantable drug delivery system of claim 1 wherein the biodegradable polymer comprises polylactide or a lactide-co-glycolide copolymer.

Claim 3: (original) The surgically implantable drug delivery system of claim 1 comprising 50 to 100% polylactide and 0 to 50% polyglycolide.

Attorney Docket No.: **PENN-0789**
Inventors: **Siegel et al.**
Serial No.: **10/046,504**
Filing Date: **October 19, 2001**
Page 4

Claim 4: (currently amended) A method of producing a ~~surgically implantable drug delivery system~~ an implant which is surgically implanted underneath the skin of a patient for delivery of steady state concentrations of haloperidol to the patient for five months or more comprising:

- (a) dissolving haloperidol and a biodegradable polymer in acetone;
- (b) solvent casting the haloperidol and biodegradable polymer solution to produce a completely dry haloperidol-polymer material; and
- (c) molding under compression the dry haloperidol-polymer material into ~~a surgical~~ an implant which is surgically implanted underneath the skin of a patient and is removable following implantation into a patient in the event the patient exhibits unwanted side effects following implantation.

Claim 5: (original) The method of claim 4 wherein the biodegradable polymer comprises polylactide or a lactide-co-glycolide copolymer.

Claim 6: (original) The method of claim 4 wherein the biodegradable polymer comprises 50 to 100% polylactide and 0 to 50% polyglycolide.

Attorney Docket No.: **PENN-0789**
Inventors: **Siegel et al.**
Serial No.: **10/046,504**
Filing Date: **October 19, 2001**
Page 5

Claim 7: (original) A method for treating patients with psychotic conditions and diseases comprising surgically implanting into a patient suffering from a psychotic condition or disease the surgically implantable drug delivery system of claim 1.

Claim 8: (original) The method of claim 7 wherein the surgically implantable drug delivery system is implanted under the skin of a patient between the muscle and dermis.

Claim 9: (original) The method of claim 7 wherein the patient is suffering from schizophrenia.

Claim 10: (original) The method of claim 7 further comprising administering to the patient an antipsychotic drug orally.